大家可以尝试自制蜜酒冬瓜汁,降眼压效果好。取冬瓜100 g,去皮榨汁,然后加入蜂蜜20 g,再用红葡萄酒50 m L调匀即可饮用,隔天1次,连用2周。蜂蜜和红葡萄酒可以提高血液的渗透压,使房水减少,从而达到降眼压的目的。冬瓜具有清热解毒,利水...大家可以尝试自制蜜酒冬瓜汁,降眼压效果好。取冬瓜100 g,去皮榨汁,然后加入蜂蜜20 g,再用红葡萄酒50 m L调匀即可饮用,隔天1次,连用2周。蜂蜜和红葡萄酒可以提高血液的渗透压,使房水减少,从而达到降眼压的目的。冬瓜具有清热解毒,利水消肿的功效,三者合用能降眼压,还可预防青光眼。展开更多
Purpose: To compare latanoprost with the fixed-combination latanoprost-timolol in glaucoma or ocular hypertension patients switched from a combination glaucoma therapy with timolol and another nonprostaglandin medicat...Purpose: To compare latanoprost with the fixed-combination latanoprost-timolol in glaucoma or ocular hypertension patients switched from a combination glaucoma therapy with timolol and another nonprostaglandin medication. Design: Prospective randomized clinical trial. Methods: Glaucoma or ocular hypertension patients receiving a combined treatment of timolol 0.5% and another nonprostaglandin medication (pilocarpine 4% , α -agonist, or a topical carbonic anhydrase inhibitor) underwent a 30- day washout of their medications. A masked observer then measured their intraocular pressure (IOP). The subjects were randomized to either latanoprost or fixed-combination latanoprost-timolol eyedrops to use once daily at 7 am. The IOP was measured again 30 days after the patients started using one of the study drugs by the same examiner at the same time. Main Outcome Measure: Comparison of the study medications’ hypotensive effect. Results: Fifty-three eyes (28 in the latanoprost group and 25 in the latanoprost-timolol group) from 28 patients were included in the study. The IOP reduction was greater in both study groups compared with the previous combination therapy with timolol and another nonprostaglandin medication in millimeters of mercury (7.7± 2.3 vs. 5.5± 2.3, P < 0.001, for the latanoprost group; 8.5± 3.5 vs. 6.3± 2.7, P < 0.001, for the latanoprost-timolol group) and percentage (35.8± 8.2% vs. 25.6± 8.9% , P < 0.001, for the latanoprost group; 38.6± 8.7% vs. 28.6± 9.0% , P < 0.001, for the latanoprost-timolol group). There was no statistical difference between latanoprost and fixed-combination latanoprost-timolol in reducing IOP, in either millimeters of mercury (P=0.3) or percentage (P=0.2). Conclusions: Both latanoprost and fixed-combination latanoprost-timolol may be viable substitutes for timolol and another nonprostaglandin medication in glaucoma or ocular hypertension patients.展开更多
文摘Purpose: To compare latanoprost with the fixed-combination latanoprost-timolol in glaucoma or ocular hypertension patients switched from a combination glaucoma therapy with timolol and another nonprostaglandin medication. Design: Prospective randomized clinical trial. Methods: Glaucoma or ocular hypertension patients receiving a combined treatment of timolol 0.5% and another nonprostaglandin medication (pilocarpine 4% , α -agonist, or a topical carbonic anhydrase inhibitor) underwent a 30- day washout of their medications. A masked observer then measured their intraocular pressure (IOP). The subjects were randomized to either latanoprost or fixed-combination latanoprost-timolol eyedrops to use once daily at 7 am. The IOP was measured again 30 days after the patients started using one of the study drugs by the same examiner at the same time. Main Outcome Measure: Comparison of the study medications’ hypotensive effect. Results: Fifty-three eyes (28 in the latanoprost group and 25 in the latanoprost-timolol group) from 28 patients were included in the study. The IOP reduction was greater in both study groups compared with the previous combination therapy with timolol and another nonprostaglandin medication in millimeters of mercury (7.7± 2.3 vs. 5.5± 2.3, P < 0.001, for the latanoprost group; 8.5± 3.5 vs. 6.3± 2.7, P < 0.001, for the latanoprost-timolol group) and percentage (35.8± 8.2% vs. 25.6± 8.9% , P < 0.001, for the latanoprost group; 38.6± 8.7% vs. 28.6± 9.0% , P < 0.001, for the latanoprost-timolol group). There was no statistical difference between latanoprost and fixed-combination latanoprost-timolol in reducing IOP, in either millimeters of mercury (P=0.3) or percentage (P=0.2). Conclusions: Both latanoprost and fixed-combination latanoprost-timolol may be viable substitutes for timolol and another nonprostaglandin medication in glaucoma or ocular hypertension patients.
